JP2002532557A5 - - Google Patents

Download PDF

Info

Publication number
JP2002532557A5
JP2002532557A5 JP2000589208A JP2000589208A JP2002532557A5 JP 2002532557 A5 JP2002532557 A5 JP 2002532557A5 JP 2000589208 A JP2000589208 A JP 2000589208A JP 2000589208 A JP2000589208 A JP 2000589208A JP 2002532557 A5 JP2002532557 A5 JP 2002532557A5
Authority
JP
Japan
Prior art keywords
group
present
imidazoacetyl
imidazopropionyl
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000589208A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002532557A (ja
JP4689833B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/030395 external-priority patent/WO2000037098A1/en
Publication of JP2002532557A publication Critical patent/JP2002532557A/ja
Publication of JP2002532557A5 publication Critical patent/JP2002532557A5/ja
Application granted granted Critical
Publication of JP4689833B2 publication Critical patent/JP4689833B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000589208A 1998-12-22 1999-12-21 グルカゴン様ペプチド−1の貯蔵安定性製剤 Expired - Fee Related JP4689833B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11349998P 1998-12-22 1998-12-22
US60/113,499 1998-12-22
PCT/US1999/030395 WO2000037098A1 (en) 1998-12-22 1999-12-21 Shelf-stable formulation of glucagon-like peptide-1

Publications (3)

Publication Number Publication Date
JP2002532557A JP2002532557A (ja) 2002-10-02
JP2002532557A5 true JP2002532557A5 (cg-RX-API-DMAC10.html) 2007-02-01
JP4689833B2 JP4689833B2 (ja) 2011-05-25

Family

ID=22349808

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000589208A Expired - Fee Related JP4689833B2 (ja) 1998-12-22 1999-12-21 グルカゴン様ペプチド−1の貯蔵安定性製剤

Country Status (9)

Country Link
EP (1) EP1140148B1 (cg-RX-API-DMAC10.html)
JP (1) JP4689833B2 (cg-RX-API-DMAC10.html)
AT (1) ATE307603T1 (cg-RX-API-DMAC10.html)
AU (1) AU2373400A (cg-RX-API-DMAC10.html)
CA (1) CA2358107C (cg-RX-API-DMAC10.html)
DE (1) DE69928006T2 (cg-RX-API-DMAC10.html)
DK (1) DK1140148T3 (cg-RX-API-DMAC10.html)
ES (1) ES2249933T3 (cg-RX-API-DMAC10.html)
WO (1) WO2000037098A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12702698B2 (en) 2017-08-24 2026-08-11 Novo Nordisk A/S GLP-1 compositions and uses thereof

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US6663602B2 (en) 2000-06-16 2003-12-16 Novo Nordisk A/S Injection device
WO2002043709A1 (fr) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
ES2298378T3 (es) * 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
EP1448222A4 (en) 2001-10-19 2006-05-17 Lilly Co Eli BIPHASIC MIXTURES OF GLP-1 AND INSULIN
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
BRPI0408978B8 (pt) 2003-04-08 2021-07-27 Novo Nordisk As processos para regenerar uma fase estacionária cromatográfica
WO2004089985A1 (en) * 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
EP1633391B1 (en) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
KR101308912B1 (ko) * 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 안정화된 약학적 펩티드 조성물
ES2375056T3 (es) * 2003-06-03 2012-02-24 Novo Nordisk A/S Composiciones pept�?dicas farmacéuticas estabilizadas.
AU2004243531B2 (en) * 2003-06-03 2009-11-05 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
KR101243648B1 (ko) * 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
JP4965446B2 (ja) 2004-08-31 2012-07-04 ノヴォ ノルディスク アー/エス ペプチド、ポリペプチド及びタンパク質の安定化のためのトリス(ヒドロキシメチル)アミノメタンの使用
PL1804865T3 (pl) 2004-10-21 2010-03-31 Novo Nordisk As Mechanizm wkręcania dla nawijanych penów
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
ES2575984T3 (es) * 2004-11-12 2016-07-04 Novo Nordisk A/S Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
CN101861333A (zh) 2007-11-16 2010-10-13 诺沃-诺迪斯克有限公司 包含glp-1肽或毒蜥外泌肽-4和基础胰岛素肽的药物组合物
BRPI0923853A2 (pt) * 2008-12-29 2016-01-12 Panacea Biotec Ltd análogos de gpl-1 e usos dos mesmos.
US20120231022A1 (en) 2009-05-28 2012-09-13 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for sleep enhancement
WO2011056713A2 (en) 2009-11-03 2011-05-12 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for obstructive sleep apnea
WO2012088157A2 (en) 2010-12-22 2012-06-28 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonists for islet cell transplantation
MX2014007375A (es) 2011-12-29 2014-08-22 Novo Nordisk As Jeringa autoinyectora de cuerda basada en resorte de torsion con mecanismo dosificador giratorio de aumento/disminucion.
KR20140138900A (ko) * 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
CN117106085A (zh) 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
EP4480537A3 (en) 2017-01-17 2025-03-12 Amgen Inc. Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
CA3062194A1 (en) 2017-06-20 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JP7250706B2 (ja) 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体(gipr)に対するアンタゴニスト結合タンパク質/glp-1受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
WO2020208541A1 (en) * 2019-04-08 2020-10-15 Enzene Biosciences Limited Composition comprising glp-1 analogue
WO2021053578A1 (en) * 2019-09-19 2021-03-25 Dr. Reddy’S Laboratories Limited Improved purification processes for liraglutide
WO2021142733A1 (en) * 2020-01-16 2021-07-22 Shanghai Benemae Pharmaceutical Corporation Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
JP2583257B2 (ja) * 1986-05-05 1997-02-19 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン向性ホルモン
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
DE69529998D1 (de) * 1994-12-23 2003-04-24 Novo Nordisk As Glp-1 zusammensetzungen mit verlängerter wirkdauer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12702698B2 (en) 2017-08-24 2026-08-11 Novo Nordisk A/S GLP-1 compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2003519099A5 (cg-RX-API-DMAC10.html)
JPH1072351A5 (cg-RX-API-DMAC10.html)
JP2003531118A5 (cg-RX-API-DMAC10.html)
JPH101422A5 (cg-RX-API-DMAC10.html)
JP2004532209A5 (cg-RX-API-DMAC10.html)
JP2003506465A5 (cg-RX-API-DMAC10.html)
RU2004127916A (ru) Способ введения молекул glp-1
JP2023534131A5 (cg-RX-API-DMAC10.html)
LU91442I2 (fr) "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"
JP2004538039A5 (cg-RX-API-DMAC10.html)
JP2006516098A5 (cg-RX-API-DMAC10.html)
JP2007503202A5 (cg-RX-API-DMAC10.html)
JP2002524024A5 (cg-RX-API-DMAC10.html)
JP2006526031A5 (cg-RX-API-DMAC10.html)
JP2002332234A5 (cg-RX-API-DMAC10.html)
JP2002503673A5 (cg-RX-API-DMAC10.html)
JP2004534850A5 (cg-RX-API-DMAC10.html)
JP2007508034A5 (cg-RX-API-DMAC10.html)
DZ3156A1 (fr) Nouvelle forme polymorphe du sel d'acide 5-Ä4-Ä2-(n-methyl-n-(2-pyridyl)amino)ethoxyÜbenzylÜthiazolidine-2,4-dione, maleique.
JP2002506864A5 (cg-RX-API-DMAC10.html)
RU2000100362A (ru) Применение специфического антагониста 5нт2 рецепторов для приготовления лекарств, пригодных для лечения синдрома апноэ во сне
JP2004532226A5 (cg-RX-API-DMAC10.html)
JP2005517783A5 (cg-RX-API-DMAC10.html)
JP2002540769A5 (cg-RX-API-DMAC10.html)
JP2003522185A5 (cg-RX-API-DMAC10.html)